menu
    • menu
    [{"orgOrder":0,"company":"Reyon Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"||Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Reyon Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reyon Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Reyon Pharmaceutical Co., Ltd \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for DKB-AHB

    Menu

    DKB-AHB

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Reyon Pharmaceutical Co., Ltd

                            South Korea arrow
                            CPhI Korea
                            Not Confirmed

                            Reyon Pharmaceutical Co., Ltd

                            South Korea arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teicoplanin,Arbekacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            REYON's Teicoplanin and Arbekacin Enter Preclinical Trials for COVID-19

                            Details : Teicoplanin is a glycopeptide antibiotic, which is being evaluated in combination with arbekacin sulfate for the treatment of covid-19.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            October 06, 2020

                            Lead Product(s) : Teicoplanin,Arbekacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kobe University

                            Country arrow
                            CPhI Korea
                            Not Confirmed

                            Kobe University

                            Country arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arbekacin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Japan Medical Association | Nobelpharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscula...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 07, 2013

                            Lead Product(s) : Arbekacin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Japan Medical Association | Nobelpharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            U.S. Army Medical Research and Development Command

                            Country arrow
                            CPhI Korea
                            Not Confirmed

                            U.S. Army Medical Research and Development Command

                            Country arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arbekacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Meiji Seika Pharma | Uniformed Services University of the Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 07, 2012

                            Lead Product(s) : Arbekacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Meiji Seika Pharma | Uniformed Services University of the Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth